Miles A Nunn Selected Research

Complement C5 (Complement 5)

1/2022	Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.
1/2016	Structural basis for therapeutic inhibition of complement C5.
6/2014	Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice.
1/2013	Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Miles A Nunn Research Topics

Disease

5	Inflammation (Inflammations) 01/2021 - 08/2015
4	Sepsis (Septicemia) 01/2017 - 06/2014
3	Human Influenza (Influenza) 01/2013 - 01/2007
2	Bullous Pemphigoid (Pemphigoid) 01/2022 - 01/2019
2	Uveitis 01/2021 - 01/2021
2	Infections 01/2013 - 01/2007
1	Neuralgia (Stump Neuralgia) 01/2022
1	Vascular Diseases (Vascular Disease) 01/2021
1	Posterior Uveitis 01/2021
1	Retinal Vasculitis 01/2021
1	Disease Progression 01/2021
1	Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa) 01/2019
1	Skin Diseases (Skin Disease) 01/2019
1	Blister (Bulla) 01/2019
1	Cytokine Release Syndrome 06/2014
1	Acute Lung Injury 06/2013
1	Lung Injury 01/2013
1	Necrosis 07/2010
1	Tick Bites 06/2007

Drug/Important Bio-Agent (IBA)

6	Complement System Proteins (Complement)IBA 01/2019 - 01/2013
4	Leukotriene B4IBA 01/2022 - 06/2013
4	Complement C5 (Complement 5)IBA 01/2022 - 01/2013
3	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2017 - 08/2015
2	CytokinesIBA 01/2021 - 07/2010
2	Retinaldehyde (Retinal)IBA 01/2021 - 01/2021
2	Oseltamivir (Tamiflu)FDA Link 11/2008 - 01/2007
1	Carrier Proteins (Binding Protein)IBA 01/2022
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2022
1	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 01/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	LeukotrienesIBA 01/2021
1	Factor V (Coagulation Factor V)IBA 01/2019
1	AnaphylatoxinsIBA 01/2016
1	Pattern Recognition ReceptorsIBA 06/2014
1	Antigen-Antibody Complex (Immune Complex)IBA 06/2013
1	LipocalinsIBA 06/2013
1	Immunoglobulin M (IgM)IBA 01/2013
1	AntigensIBA 07/2010
1	Interleukin-12 (IL 12)IBA 07/2010
1	Fatty Acids (Saturated Fatty Acids)IBA 06/2007
1	Antiviral Agents (Antivirals)IBA 01/2007

Therapy/Procedure

1	Intravenous Infusions 01/2017
1	Anesthesia 11/2015
1	Critical Care (Surgical Intensive Care) 11/2015
1	Ligation 06/2014
1	Punctures 06/2014
1	Therapeutics 06/2014
1	Intraperitoneal Injections 01/2013